allogeneic GM-CSF-secreting breast cancer vaccine

BIOLOGICAL5 trials

Sponsors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Wiseman Research Initiatives LLC

Conditions

Breast CancerBreast NeoplasmsUnspecified Adult Solid Tumor, Protocol Specific

Phase 1

Vaccine Therapy With or Without Cyclophosphamide and Doxorubicin in Women With Stage IV Breast Cancer

CompletedNCT00093834

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBreast Cancer

Start: 2004-01-31Target: 60Updated: 2023-07-03

Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers

TerminatedNCT00095862

Wiseman Research Initiatives LLCBreast Cancer, Unspecified Adult Solid Tumor, Protocol Specific

Start: 2004-11-30Target: 24Updated: 2018-02-05

Phase 2

Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine for the Treatment of HER-2/Neu-Overexpressing Metastatic Breast Cancer

CompletedNCT00399529

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBreast Neoplasms

Start: 2006-09-30End: 2010-02-28Updated: 2020-04-22

Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer

CompletedNCT00847171

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBreast Cancer

Start: 2008-12-31End: 2013-06-30Updated: 2018-09-26

Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer

CompletedNCT00971737

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBreast Cancer

Start: 2009-07-31End: 2016-03-31Updated: 2019-04-24

Related Papers

Regression of Breast Cancer Metastases Following Treatment withIrradiated SV-BR-1-GM, a GM-CSF Overexpressing Breast Cancer CellLine: Intellectual Property and Immune Markers of Response

Recent Patents on Anti-Cancer Drug Discovery2022-05-208 citations

Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab

Journal for ImmunoTherapy of Cancer2019-10-2332 citations

SV-BR-1-GM, a Clinically Effective GM-CSF-Secreting Breast Cancer Cell Line, Expresses an Immune Signature and Directly Activates CD4+ T Lymphocytes

Frontiers in Immunology2018-05-1522 citations

Abstract OT3-01-06: A phase I/IIa study of the whole-cell vaccine BriaVax™ in metastatic or locally recurrent breast cancer patients (NCT00095862)

Cancer Research2017-02-15